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Eight mutations including 5 novel ones in the COL1A1 gene in Czech patients  
with osteogenesis imperfecta
Lucie Hruskovaa, Igor Fijalkowskib, Wim Van Hulb, Ivo Marikc,d, Geert Mortierb, Pavel Martaseka, Ivan Mazuraa
Background and Aim. Osteogenesis imperfecta (OI), also called brittle bone disease, is a clinically and genetically 
heterogeneous disorder characterized by decreased bone density. Autosomal dominant forms result from mutations 
in either the COL1A1 (collagen type I alpha-1 chain) or COL1A2 (collagen type I alpha-2 chain) genes encoding the 
type I collagen. The aim of this study was to identify mutations and allelic variants of the COL1A1 gene in patients with 
osteogenesis imperfecta (OI).
Methods and Results. Molecular genetic analysis of the COL1A1 gene was performed in a cohort of 34 patients with 
OI. The DNA samples were analysed by PCR and Sanger sequencing. DNA changes in coding sequences of the gene 
were compared with Type 1 Collagen Mutation Database. Genetic variants resulting in either quantitatively or struc-
turally defective protein production were found in 6 unrelated patients. Four identified mutations are connected to 
decreased protein production (Tyr47X, Arg131X, Arg415X, Gln1341X), 2 result in amino acid substitution (Cys61Phe, 
Pro1186Ala) and the last affects splicing (c.1057-1G>T).  Further, one silent mutation (Gly794Gly) was detected. No 
protein analysis was performed.
Conclusion. Of the 8 identified mutations, 5 were novel and have not been reported before. Only one causes substitu-
tion of glycine located within the Gly-X-Y triplets in the triple helical domain. Two mutations are located in major ligand 
binding regions (MLBR) which are important for bone strength and flexibility. Although the genotype-phenotype 
correlation is still unclear, our findings should contribute to elucidating this relationship in patients diagnosed with OI.
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INTRODUCTION
osteogenesis imperfecta (oi) is a disorder of human 
connective tissue characterized by low bone mass and 
decreased bone material strength resulting in a higher 
risk of fractures. affected patients show variable clinical 
signs such as blue sclerae, hearing loss, joint hypermo-
bility, skin hyperlaxity, normal to low stature and den-
tinogenesis imperfecta (di). skeletal radiographs reveal 
osteopenia and pathological fractures of long bones and/
or vertebrae. Based on clinical and genetic features four-
teen types of the disease (type i to XiV) have been delin-
eated to date. depending on the genetic basis, two forms 
of oi – collagenous (types i to iV) and non-collagenous 
(types V to XiV), are described1. about 90% of oi cases 
are due to dominant mutations in either the col1a1 
(collagen type i alpha-1 chain) gene or col1a2 (colla-
gen type i alpha-2 chain) gene both of which encode the 
type i collagen protein.  These mutations result in either 
reduced production (haploinsufficiency) of the protein 
or in the synthesis of structurally abnormal collagen1,2. 
Haploinsufficiency results from mutations creating stop-
codons (premature termination codon) indicating tran-
scription termination of affected gene. such shortened 
alpha chains miss c-propeptide domain which is impor-
tant for alpha chains assembling into triple helix and are 
destroyed by a process called nonsense-mediated decay. 
This process eliminates mutant alpha chains and leads 
to the synthesis of reduced amount of normal protein. 
decreased production (haploinsufficiency) of collagen 
type i is typical for oi type i (ref.1,3,4). patients affected 
by oi type i (dominantly inherited oi with blue sclerae) 
are of normal stature and have blue sclera (probability 
of blue sclerae occurrence is near to 100% (ref.5)). Bone 
fractures occur especially during childhood and moderate 
bone deformities, especially of the lower limbs and spine, 
could be observed. other clinical sign observed in oi type 
i individuals is hearing impairment which usually results 
in hearing loss4. Based on presence of dental abnormali-
ties, type i is divided into a and B subtypes (with and 
without dentinogenesis imperfecta, respectively) (ref.2,6). 
in general, patients affected with oi type ia are of normal 
stature and have lower incidence of fractures whereas oi 
type iB patients have higher frequency of fractures and 
more skeletal deformities resulting in shorter stature5,7. 
synthesis of abnormal collagen type i is described in oi 
types ii, iii and iV. mutations affecting the structure of 
alpha chains include amino acids substitutions, exon-skip-
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ping mutations and more complex gene rearrangements3. 
oi type ii (lethal perinatal oi with radiographically 
crumpled femora and beaded ribs) is a lethal type of oi 
with high percentage of perinatal mortality. in rare cases, 
patients survive few days. Typical clinical signs include 
multiple intrauterine fractures, severe skeletal deformi-
ties, blue sclera, low birthweight and low birth crown-heel 
length8,9. The third type of oi (progressively deforming 
oi with normal sclerae) is the most severe form char-
acterised by progressive deformities, high frequency of 
fractures, short stature due to severe skeletal deformities, 
triangular face, hearing impairment, basilar impression 
and dentinogenesis imperfecta. in some cases, infants 
die due to cardiac or pulmonary insufficiency8,9. The last 
type of oi with origin in defective collagen type i produc-
tion, oi type iV (dominantly inherited oi with normal 
sclerae), is the most heterogeneous form of the disease. 
individuals exhibit mild to moderate phenotype and are 
of short stature. First fractures occur at birth, moderate 
deformities (especially of long bones of the lower and up-
per limbs) are presented. Teeth and hearing impairment 
could be presented5. like the first oi type, subtypes a and 
B (with and without di, respectively) are distinguished2,6. 
in the remaining 10% of cases, oi is the result of reces-
sive mutations in iFiTm5 (interferon-induced transmem-
brane protein 5, oi type V; bone formation co-participant) 
(ref.10), serpiNF1 (serpin peptidase inhibitor, clade F, 
member 1, oi type Vi; bone mineralization participation) 
(ref.11), crTap (cartilage associated protein, oi type Vii; 
3-hydroxylation complex component) (ref.12), p3H1 (prolyl 
3-Hydroxylase 1, oi type Viii; 3-hydroxylation complex 
component) (ref.12,13), ppiB (peptidyl-prolyl isomerase 1 
(cyclophylin B), oi type iX; 3-hydroxylation complex com-
ponent) (ref.14), serpiNH1 (serpin peptidase inhibitor, 
clade H, member 1, oi type X; collagen type I chaperone) 
(ref.12), FKBp10 (FK506-binding protein 10, oi type Xi; 
collagen type I chaperone) (ref.12), sp7 (osteoblast-specific 
transcription factor sp7, oi type Xii; cell differentiation co-
participant) (ref.11), Bmp1 (Bone morphogenetic protein 
1, oi type Xiii; embryogenesis and skeletogenesis process 
co-participant) (ref.11,15) or Tmem38B (Transmembrane 
protein 38B, oi type XiV; cell differentiation co-participant) 
(ref.11). recently, mutations in the WNT1 gene (Wingless-
type mmTV integration site family, member 1, bone mass 
regulator) have been described in patients diagnosed with 
oi type iV (ref.16). 
The incidence of oi ranges from 1:25000-40000 (non-
lethal forms) to 1:50000 (lethal forms) live births in the 
world17. currently, no data are available on oi prevalence 
in the czech population. 
The aim of this study is identification of mutations 
and allelic variants of col1a1 gene. Type i collagen 
is a heterotrimer, composed of two alpha-1(i) and one 
alpha-2(i) chain encoded by col1a1 and col1a2 re-
spectively. alpha-1(i) chain represents 2/3 of this hetero-
trimer1. Generally, in the random selection of abnormal 
chains 75% of mutant heterotrimers contain one or more 
defective alpha-1(i) chains4. Further, possible genotype-
phenotype relationship of identified mutations will be 
discussed. determination of possible effect of identified 
mutations on clinical picture of affected patients could be 
helpful for providing well-timed and helpful treatment of 
affected individuals.  
MATeRIALS AND MeTHODS
Material
included in the study were 34 patients with a diagnosis 
of oi. There were 11 males and 23 females aged 7 to 57 
years. The diagnosis was based on evaluation of clinical, 
radiological and biochemical features. in 19 patients, a 
diagnosis of oi type ia was made, 6 individuals were af-
fected by type iii, in 4 cases oi type iVa was identified 
and 5 patients suffered from type iVB. No case of oi type 
ii was included in the study. 
This study was performed in accordance with prin-
ciples of the declaration of Helsinki and approved by 
the ethics committee of General University Hospital in 
prague (project 83/14). participants provided their writ-
ten informed consent with involvement in the study. The 
purpose and procedures of the research were explained, 
rights to refrain from the study under any circumstanc-
es and for any reason were emphasized. informed con-
sent was ensured by the ambulant centre for defects 
of locomotor apparatus in prague and was carried out 
according to “informed approbation in medical genet-
ics” by the committee of the society of medical Genetics 
(smG) czech medical association of J. e. purkyne.
Laboratory methods
Genetic analysis was restricted to the coding (and 
f lanking non-coding) sequences (51 exons) of the 
col1a1 gene whose product (alpha-1(i) chain) is two 
copies in the collagen type i (ref.18). Genomic dNa 
was extracted from peripheral blood leukocytes using 
a standard extraction method (Qiaamp dNa Blood 
midi Kit, QiaGeN), followed by high resolution melt-
ing analysis (Hrm), polymerase chain reaction (pcr) 
amplification and sanger sequencing. pcr amplifica-
tion was performed using 47 sets of forward and reverse 
primers located in sequences of flanking introns (primer 
sequences are available on request). pcr products were 
confirmed by horizontal gel electrophoresis. sequences 
of these pcr products were obtained on the aBi prism 
3130xl Genetic analyzer automated sequencer (applied 
Biosystems, Foster city, ca, Usa) using the Bigdye ter-
minator cycle sequencing chemistry. The data were com-
pared to the wild-type sequence as submitted to ensembl 
accession no. eNsT00000225964. Nucleotides were 
numbered from the first base of the start codon (aTG) 
of the cdNa reference sequence according to GenBank 
Nm_000088.3. amino-acid residues were numbered 
from the start codon for methionine (aTG) of the alpha-1 
chain of type i collagen (reference sequence GenBank 
Nm_000079.2).
Novel mutations were identified by their absence 
from the osteogenesis imperfecta Variant database, col-
lagen, type i, alpha 1 (col1a1) (https://oi.gene.le.ac.
uk/home.php?select_db=col1a1) and the osteogenesis 
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Table 1. Basic clinical and personal data and genetic findings of osteogenesis imperfecta (oi)  
probands with col1a1 mutations.
Nucleotide changei c.141c>a c.182G>T c.391c>T c.1243c>T 
c.3556 c>G
c.4021c>T c.1057-1G>T c.2382T>c
predicted amino 
acid changeii
Tyr47X cys61phe arg131X arg415X 
pro1186ala
Gln1341X splice-site 
mutation
Gly794Gly
Hr/Hmiii Hr Hm Hr Hr Hr Hr Hr Hr
protein defect quantitative qualitative quantitative quantitative
qualitative
quantitative qualitative silent  
mutation
sNp propertyi exon 2 exon 2 exon 5 exon 19
exon 48
exon 50 intron 16 exon 34
Novel Yes No No Yes
No
Yes Yes Yes
oi patient oi17 oi23 oi42 oi14 oi2 oi21 oi30
sexiV F m F m m m F
age (years) 23 45 24 22 18 50 24
Type of oi ia iii ia ia ia ia/iVa iVa
s/FV s s F s s F s
Blue scleraVi - - - + + + +/-
Hearing lossVi - - - - - + -
Bone deformitiesVi - + + + + + +
i The numbering for the nucleotide changes and exons are based on cdNa sequence in accordance with GenBank entry Nm_000088.3.
ii Numbered with reference to the a of initiation aTG as 1 according to the reference sequence Np_000079.2.
iii Hr: heterozygous allele state; Hm: homozygous allele state
iV m: male; F: female
V F: familial oi case; s: sporadic oi case
Vi +: presence of clinical sign; -: absence of clinical sign; +/-: clinical sign changed with age; x: no data
Fig. 1. localization of identified col1a1 gene mutations. The exons are presented by vertical lines. multi ligand Binding regions 
are represented by boxes in shades of grey.
imperfecta Variant database, collagen, type i, alpha 2 
(col1a2) (https://oi.gene.le.ac.uk/home.php?select_
db=col1a2). possible splice site effect of novel in-
tronic mutation was evaluated using the pc program 
alamut (used algorithms: splicesiteFinder, maxentscan, 
NNsplice, Genesplicer, Human splicing Finder).
ReSULTS
We identified col1a1 mutations of coding and 
non-coding sequences in 7/34 patients. None of these 
mutations were found in the dNa of a healthy con-
trol – caucasian population. Four of the mutations 
result in premature stopcodon (c.141c>a p.Tyr47X, 
c.391c>T p.arg131X, c.1243c>T p.arg415X, c.4021c>T 
p.Gln1341X), two are missense mutations (c.182G>T 
p.cys61phe, c.182G>T p.pro1186ala), one is located 
in intronic sequence (c.1057-1G>T) and the last one is 
silent mutation of glycine at position 794 of the col1a1 
gene (Table 1, Fig. 1). 
The first patient (oi17) in this study was a 23-year-old 
woman affected by oi type ia. she is of subnormal height 
and suffers from joint hypermobility. in this case, we iden-
tified the heterozygous p.Tyr47X mutation in col1a1. 
The second case (oi23) was a 45-year-old man of 
unaffected parents diagnosed with oi type iii. He had 
had multiple fractures since childhood, especially of the 
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lower limbs, and is confined to a wheelchair. He has a 
barrel-shaped chest, severe bone deformities and muscle 
weakness in the lower limbs. We identified homozygous 
substitution of cysteine by phenylalanine at position p.61 
in the dNa sample of this individual. This mutation from 
the program alamut was predicted as disease causing (P 
= 1.0). 
The third case (oi42) was a 24-year-old woman suf-
fering from oi type ia. she is of subnormal height and 
has a mild barrel-shaped chest. dNa analysis identified 
a premature stopcodon at residue p.131 coding for argi-
nine. she has four other affected relatives; unfortunately 
their dNa samples were not available.
The next case was a 22-year-old young man (oi14) 
suffering from oi type ia. He shows blue sclerae, has 
a relatively short barrel-shaped chest and mild deforma-
tion of the lower limbs and vertebrae. in this patient, we 
identified a heterozygous p.arg415X mutation in exon 
19. even though it is represented in a sequence database 
(rs72648326), it is disease causing due to production of 
shortened alpha chains with loss of heterotrimer forma-
tion function. Further, a substitution of proline by ala-
nine at position p.1186 was also identified in heterozygous 
state. This mutation, using the program alamut, was pre-
dicted as disease causing (P = 0.998).
The patient with an identified mutation in the coding 
sequence of the col1a1 gene, p.Gly1341X in heterozy-
gous state, was an 18-year-old boy (oi2) affected by oi ia. 
The boy is of subnormal height. He has light blue sclerae, 
barrel-shaped chest and muscle hypotrophy of the limbs. 
He had suffered from multiple fractures of the spine and 
both upper and lower limbs. 
The heterozygous change c.1057-1G>T was identified 
in the dNa of a 50-year-old man (oi21) with clinical 
phenotype corresponding with type ia/iVa of the disease. 
He suffered from multiple fractures of the limbs since 
childhood. He has blue sclerae, deformed bones and suf-
fers from hearing loss. 
Further, genetic analyses of the 34 patients identified 
38 polymorphisms in the col1a1 gene. This also in-
cludes a silent heterozygous variant of glycine at position 
p.794 of the col1a1 gene identified in the case of a 
24-year-old woman (oi30) diagnosed with oi iVa. she 
suffered multiple fractures of the lower limbs until the age 
of 18. The patient is of subnormal height, has deformed 
lower limb bones and weak muscles. she also showed 
joint hypermobility. The sclera had been light blue after 
the birth but had whitened during childhood. This patient 
was treated with bisphosphonates until the age of 21. Nine 
of 38 identified polymorphisms were situated in coding 
sequence, 7 were localised in mlBrs and one occurred 
in 3´untranslated region of the gene. allele frequencies 
of polymorphisms identified in oi patients correlate 
with population genetics available on ensembl data-
base (http://www.ensembl.org/Homo_sapiens/Transcript/
Variation_Transcript/Table?db=core;g=eNsG000001088
21;r=17:50183289-50201632;t=eNsT00000225964). 
DISCUSSION
all of the identified mutations resulting in decreased 
production of collagen type i (c.141c>a p.Tyr47X, 
c.391c>T p.arg131X, c.1243c>T p.arg415X, c.4021c>T 
p.Gln1341X) were found in patients affected by oi type 
i. except one case (p.arg131X, oi42), it was the first oc-
currence of the disease in the family history. Furthermore, 
in all cases we were able to observe one common clinical 
sign – subnormal body height. only the arg131X had 
been described in the case of italian patients with a posi-
tive oi family history (the mutant allele was also detected 
in the mother of the individual). Unfortunately, the clini-
cal data on this individual are not available19. 
The nucleotide change c.182G>T results in substitu-
tion p.cys61phe in the col1a1 gene. The identified 
mutation is in a homozygous state and is localized on 
the second exon of the col1a1 gene which is a part 
of the N-terminal propeptide domain of the pro-alpha-
1(i) collagen chain encoded by the first five exons and 
by a part of the sixth exon of the gene3. The integrity 
of N-propeptide is important for proper chain associa-
tion and for subsequent folding of individual alpha chains 
into a collagen trimer with triple helical configuration 
(the importance of structure and folding of triple helix 
is also true for c-propeptide). in this process, cysteine 
residues play a major role through formation of intra- and 
interchain disulphide bonds. during proteosynthesis, the 
N-terminal propeptide is removed from the pro-alpha-1(i) 
chain by specific proteinase to form the alpha-1(i) chain 
terminated by N-telopeptide.  Because the substitution is 
not localized close to the N-proteinase cleavage site, its oc-
currence is not likely to prevent N-propeptide removal20. 
The substitution is also localized in the von Willebrand 
factor type c (vWF-c) binding region defined by amino 
acid residues 38-96 (ref.21). although the mutation could 
delay vWF-c binding, it is unknown whether or how it 
affects collagen type i processing. This mutation was first 
described by Zhang et al. (2012) in the case of a 17-year-
old chinese boy affected by the oi type i (first occurrence 
of the disease in the family, allelic variant not described). 
clinical features described in this case were blue sclera 
and multiple fractures (more then 10) (ref.13). We found 
this change in a homozygous state in the patient diag-
nosed with the progressively deforming form of oi (type 
iii). individuals have soft, fragile, deformed bones and 
may suffer from neurologic and respiratory complications. 
The other clinical picture includes severe scoliosis, blue 
colour of sclera, hearing loss and dentinogenesis imper-
fecta22. The only clinical sign described in both cases with 
identified p.cys61phe substitution was high frequency 
of fractures.
substitution of proline by alanine at position p.1186 
of the col1a1 protein is described in a case identified 
as oi type ia. The mutation is localized in exon 48 which 
is part of the third important ligand binding region, called 
the major ligand Binding region (mlBr). There are 
three such regions (mlBr1-3) defined by codons 81–200 
(mlBr1), 682–830 (mlBr2) and 920-1040 (mlBr3) 
(codon numbers start at the first amino acid residue of the 
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Sep; 160(3):442-447.
446
helical domain of alpha chains) (ref.18,23). These regions pro-
duce intermolecular binding of collagen type i with other 
connective tissue proteins like integrins, comp (cartilage 
oligomeric matrix protein), serpinH1, phosphophoryn and 
others. These interactions result in increasing bone strength 
and elasticity18. The mlBr3 region is encoded by a part of 
exon 46, the entire exons 47 and 48 and part of the exon 
49 sequence23. concretely, this region including pro1186 
of the collagen type i molecule, binds amyloid beta a4 pre-
cursor protein (app) that mediates cell-cell interactions18. it 
is also suggested that amyloid precursor protein is implicated 
in the regulation of synapse formation, neural plasticity and 
iron export24-26. other molecules bound to this part of the 
alpha-1(i) chain are interleukin 2 (il2; regulates activity 
of T-lymphocytes) (ref.18,27) and the collagen binding factor 
eNdo180 (mannose receptor, c-type, 2; mrc2) which acts 
as collagen-binding receptor in the process of endocytosis. it 
may also play a role in the catabolism of extracellular matrix 
collagens. Finally, it is suggested this protein may participate 
in cell-matrix adhesion and cell migration18,28. The identified 
mutation disrupts the binding sequence. a further aspect is 
that p.pro1186ala substitution could negatively affect the 
stability of collagen type i. proline and hydroxyproline resi-
dues are important amino acids representing 2/3 of all the 
X and Y positions of the Gly-X-Y motive in alpha chains. 
High frequency of these two amino acids increases the sta-
bility of molecules due to creation of interactions within 
their side chains and other triple helices29. There is evidence 
that substitution of proline localized within the triple helical 
domain of the collagen protein affects thermal stability of 
the collagen fibril since denaturation temperatures increase 
with increasing content of proline and hydroxyproline resi-
dues30. This variant was also predicted to be damaging using 
algorithms mutationTester and siFT.
mutation in the intronic sequences was identified in 
one patient. Transversion G to T at position c.1057-1 in 
the col1a1 gene was found in a man affected by oi type 
iVa. Nucleotide change is situated in the acceptor splice 
site of exon 17 and has been predicted to create a new 
acceptor splice site localized one base downstream to the 
first nucleotide of the first codon for glycine (GGT) of the 
exon 17. consequently there is a shift of the reading frame 
of the exon 17 what is completely included in the mlBr1 
(ref.18). several extracellular matrix molecules are known 
to bind to this part of collagen type i. These include inter-
leukin 2 (regulation of lymphocytes activity), α2β1 integ-
rin which is able to bind other molecules of extracellular 
matrix (ecm) and Ge-decorin (guanidine-extracted deco-
rin) that appears to influence fibrillogenesis and interacts 
with other molecules of ecm (ref.18,27,31,32). Further, there 
are binding sites for osteonectin - a sodium binding glyco-
protein that increases bone mineralization, and serpinH1 
protein which ensures thermal stabilization of the triple 
helix domain during procollagen synthesis, helps the fold-
ing and assembly of procollagen molecules and partici-
pates in the transport of structurally unaffected molecules 
from the endoplasmic reticulum18,33,34. The c.1057-1G>T 
mutation results in production of structurally defective 
collagen type i with delayed binding ability of other ecm 
molecules increasing bone stability. 
The silent c.Gly794Gly variant was identified in the 
case of a patient affected by oi type iVa. even though, 
it is situated in the comp binding domain defined by 
codons 582 to 638, the variant does not alter the reading 
frame and so does not affect the protein production18.
This study is the first comprehensive analysis of pa-
tients affected by the collagenous forms of the osteogen-
esis imperfecta disease. col1a1 mutations were only 
found in 20.6% of analysed individuals. The low percent-
age could be explained by the disease causing mutations 
occurring in other genes, like col1a2, ppiB, crTap 
and others, involved in collagen type i processing and syn-
thesis, by the lower probability of detecting c/G and a/T 
single nucleotide polymorphisms and small homozygous 
insertions/deletions shift using the Hrm method as these 
may be very close in Tm to the wild type. For some exons, 
it can also be difficult to interpret Hrm results because 
of the presence of several mutations or polymorphisms35. 
additional functional experiments need to be performed 
to evaluate the effect of identified mutations. Further, 
analyses of col1a1coding sequences excluded by Hrm 
will be prepared.
currently, col1a2 genetic screening is performed 
to provide additional variants in patients diagnosed with 
one of dominant oi types. 46 of 52 coding (and flank-
ing non-coding) sequences of the gene were analysed. 
disease causing mutation of exon 40 (p.Gly814Trp) was 
identified in a patient affected by the third form of oi 
(ref.36). Further, genetic analyses identified 14 single nu-
cleotide polymorphisms. 4 were in coding sequence, 1 oc-
curred in mlBr3. allele frequencies of polymorphisms 
identified in col1a2 gene correlate with population 
genetics available on ensembl (http://www.ensembl.
org/Homo_sapiens/Transcript/Variation_Transcript/
Table?db=core;g=eNsG00000164692;r=7:94394561-
94431232;t=eNsT00000297268).
CONCLUSION
Novel candidate col1a1 mutations were identified 
in patients diagnosed with dominant oi forms. molecular-
genetic analyses of another 6/52 col2a1 coding se-
quences are currently being prepared. analyses of other 
genes involved in the disease origin are also planned as 
mutations in these genes may account for autosomal re-
cessive forms in the oi patients involved in the study. 
it could be also helpful to analyse mrNa in patients 
with identified non-coding sequences mutations to define 
the effect of dNa splicing and collagen type i production. 
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